Role and mechanisms of SGLT-2 inhibitors in the treatment of diabetic kidney disease
Open Access
- 21 September 2023
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1213473
Abstract
Diabetic kidney disease (DKD) is a chronic inflammatory condition that affects approximately 20-40% of individuals with diabetes. Sodium-glucose co-transporter 2 (SGLT-2) inhibitors, emerging as novel hypoglycemic agents, have demonstrated significant cardiorenal protective effects in patients with DKD. Initially, it was believed that the efficacy of SGLT-2 inhibitors declined as the estimated glomerular filtration rate (eGFR) decreased, which led to their preferential use in DKD patients at G1-G3 stages. However, recent findings from the DAPA-CKD and EMPA-KIDNEY studies have revealed equally beneficial cardiorenal effects of SGLT-2 inhibitors in individuals at stage G4 DKD, although the underlying mechanism behind this phenomenon remains unclear. In this comprehensive analysis, we provide a systematic review of the mechanisms and functioning of SGLT-2 inhibitors, potential renal protection mechanisms, and the therapeutic efficacy and safety of SGLT-2 inhibitors in kidney diseases, with a particular focus on stage G4 DKD. Gaining a deeper understanding of the renal protective effect of SGLT-2 inhibitors and their underlying mechanisms is highly significance for the successful utilization of these inhibitors in the treatment of diverse kidney disorders.Keywords
Funding Information
- Natural Science Foundation of Guangdong Province (2023A1515012187)
This publication has 106 references indexed in Scilit:
- Impacts of Recombinant Human Erythropoietin Treatment During Predialysis Periods on the Progression of Chronic Kidney Disease in a Large‐Scale Cohort Study (Co‐JET study)Therapeutic Apheresis and Dialysis, 2013
- Effect of Canagliflozin on Renal Threshold for Glucose, Glycemia, and Body Weight in Normal and Diabetic Animal ModelsPLOS ONE, 2012
- Canagliflozin, a novel inhibitor of sodium glucose co‐transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjectsDiabetes, Obesity and Metabolism, 2011
- The role of sympathetic nervous activity in renal injury and end-stage renal diseaseHypertension Research, 2010
- Role of the renin angiotensin system in diabetic nephropathyWorld Journal of Diabetes, 2010
- Analytical Review of the Evidence for Renoprotection by Renin-Angiotensin-Aldosterone System Blockade in Chronic Kidney Disease – A Call for CautionNephron Clinical Practice, 2009
- ACE-inhibitor use and the long-term risk of renal failure in diabetesKidney International, 2006
- Sympathetic dysfunction in type 1 diabetesJACC, 2004
- Impact of Type 2 Diabetes Mellitus on Sympathetic Neural Mechanisms in HypertensionCirculation, 2003
- Inhibition of myo-inositol transport causes acute renal failure with selective medullary injury in the ratKidney International, 1998